deferoxamine has been researched along with Bacterial Disease in 13 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Time after splenectomy >10 years, deferoxamine therapy, and iron overload may be clinical risk factors for severe bacterial infection in patients with NTDT." | 3.81 | Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors. ( Chansung, K; Jetsrisuparb, A; Sirijerachai, C; Teawtrakul, N; Wanitpongpun, C, 2015) |
| "To determine the effects of combination of deferoxamine and meropenem in acute necrotizing pancreatitis." | 3.72 | Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. ( Ateskan, U; Babaoglu, E; Comert, B; Deveci, S; Doruk, H; Kocar, IH; Mas, MR; Mas, NN; Ozkomur, ME; Tasci, I; Yasar, M, 2003) |
| " This substance is well absorbed orally and has been shown to enhance the excretion of ferric ion in iron loaded rats." | 2.36 | [Iron chelation. Biological significance and medical application]. ( Peter, HH, 1983) |
| " Our results demonstrate the importance of haemosiderosis in the increased susceptibility of haemodialysed patients to infections; this susceptibility is decreased by desferrioxamine therapy, which probably acts by restoring phagocytosis and reducing the bioavailability of iron for pathogens." | 1.28 | Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. ( Collart, FE; Dratwa, M; Lenclud, CM; Tielemans, CL; Wens, R, 1989) |
| "0." | 1.27 | Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis. ( Schaefer, K; Seifert, A; von Herrath, D, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Teawtrakul, N | 1 |
| Jetsrisuparb, A | 1 |
| Sirijerachai, C | 1 |
| Chansung, K | 1 |
| Wanitpongpun, C | 1 |
| Ateskan, U | 1 |
| Mas, MR | 1 |
| Yasar, M | 1 |
| Deveci, S | 1 |
| Babaoglu, E | 1 |
| Comert, B | 1 |
| Mas, NN | 1 |
| Doruk, H | 1 |
| Tasci, I | 1 |
| Ozkomur, ME | 1 |
| Kocar, IH | 1 |
| Matinaho, S | 1 |
| Parkkinen, J | 1 |
| Weinberg, ED | 1 |
| Rahav, G | 1 |
| Volach, V | 1 |
| Shapiro, M | 1 |
| Rund, D | 1 |
| Rachmilewitz, EA | 1 |
| Goldfarb, A | 1 |
| Peter, HH | 1 |
| Boelaert, JR | 1 |
| de Locht, M | 1 |
| Jurado, RL | 1 |
| Hoen, B | 1 |
| Kessler, M | 1 |
| Tielemans, CL | 1 |
| Lenclud, CM | 1 |
| Wens, R | 1 |
| Collart, FE | 1 |
| Dratwa, M | 1 |
| Hershko, C | 1 |
| Peto, TE | 1 |
| Weatherall, DJ | 1 |
| Tielemans, C | 1 |
| Lenclud, C | 1 |
| Seifert, A | 1 |
| von Herrath, D | 1 |
| Schaefer, K | 1 |
4 reviews available for deferoxamine and Bacterial Disease
| Article | Year |
|---|---|
Therapeutic potential of iron chelators in diseases associated with iron mismanagement.
Topics: Animals; Bacterial Infections; Deferoxamine; Free Radicals; Humans; Iron; Iron Chelating Agents; Iro | 2006 |
[Iron chelation. Biological significance and medical application].
Topics: Animals; Bacterial Infections; Catechols; Deferoxamine; Diabetes Mellitus; Enterobactin; Female; Hum | 1983 |
Iron, infections, and anemia of inflammation.
Topics: Anemia; Bacteria; Bacterial Infections; Blood Transfusion; Carrier Proteins; Conalbumin; Deferoxamin | 1997 |
Iron and infection.
Topics: Adult; Bacteria; Bacterial Infections; Deferoxamine; Disease Susceptibility; Humans; Infant; Infant, | 1988 |
1 trial available for deferoxamine and Bacterial Disease
| Article | Year |
|---|---|
[Infectious risks in patients with renal failure on hemodialysis. Importance of iron overload and deferoxamine].
Topics: Bacterial Infections; Deferoxamine; Ferritins; Humans; Incidence; Iron; Kidney Failure, Chronic; Lis | 1991 |
8 other studies available for deferoxamine and Bacterial Disease
| Article | Year |
|---|---|
Severe bacterial infections in patients with non-transfusion-dependent thalassemia: prevalence and clinical risk factors.
Topics: Adolescent; Adult; Bacterial Infections; Child; Deferoxamine; Female; Ferritins; Humans; Iron Overlo | 2015 |
Deferoxamine and meropenem combination therapy in experimental acute pancreatitis.
Topics: Acute Disease; Animals; Bacteria; Bacterial Infections; Catheterization; Deferoxamine; Drug Therapy, | 2003 |
Non-transferrin-bound iron in platelet concentrates promotes the growth of Staphylococcus epidermidis.
Topics: Antimetabolites, Antineoplastic; Bacterial Infections; Bleomycin; Blood Platelets; Citric Acid; Defe | 2005 |
Severe infections in thalassaemic patients: prevalence and predisposing factors.
Topics: Adolescent; Adult; Bacterial Infections; beta-Thalassemia; Child; Deferoxamine; Female; Ferritins; H | 2006 |
Side-effects of desferrioxamine in dialysis patients.
Topics: Bacterial Infections; Brain Diseases; Deferoxamine; Eye; Hearing Loss, Sensorineural; Humans; Iron; | 1993 |
Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine.
Topics: Aluminum; Bacterial Infections; Deferoxamine; Disease Susceptibility; Ferritins; Humans; Iron; Renal | 1989 |
Respective role of haemosiderosis and desferrioxamine therapy in the risk from infection of haemodialysed patients.
Topics: Bacterial Infections; Deferoxamine; Hemosiderosis; Humans; Renal Dialysis; Risk Factors | 1988 |
Iron overload, but not treatment with desferrioxamine favours the development of septicemia in patients on maintenance hemodialysis.
Topics: Aged; Bacterial Infections; Deferoxamine; Female; Hemosiderosis; Humans; Kidney Failure, Chronic; Ma | 1987 |